Table 3 The enriched pathway terms of the up and down regulated differentially expressed genes
Pathway ID | Pathway name | P-value | FDR B&H | FDR B&Y | Bonferroni | Gene count | Gene |
|---|---|---|---|---|---|---|---|
Up regulated genes | |||||||
1270244 | Extracellular matrix organization | 3.33E−08 | 1.80E−05 | 1.23E−04 | 1.80E−05 | 24 | COL22A1, MFAP4, CMA1, COL14A1, COL1A1, COL8A2, COL9A1, COL9A2, COL10A1, FMOD, COL16A1, COMP, HAPLN1, ADAMTS14, CTSG, ASPN, ITGAL, ITGB7, CAPN6, TGFB2, P3H2, TLL2, LTBP2, LUM |
1269201 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 8.13E−06 | 7.31E−04 | 5.03E−03 | 4.39E−03 | 13 | SH2D1B, SLAMF7, SIGLEC8, ITGAL, ITGB7, KLRB1, CD1C, CD3D, CD3E, CD3G, CD247, CD40LG, SH2D1A |
1269544 | GPCR ligand binding | 3.92E−04 | 1.51E−02 | 1.04E−01 | 2.12E−01 | 22 | GNG8, PENK, F2RL2, AGTR2, APLNR, CXCL9, CCR7, CXCL11, OXER1, HTR2A, HTR2B, WNT10B, WNT9A, ACKR4, CRHBP, S1PR5, FZD2, CX3CR1, CXCL10, MCHR1, LHCGR, GPR68 |
1268749 | Metabolism of Angiotensinogen to Angiotensins | 5.26E−04 | 1.85E−02 | 1.27E−01 | 2.84E−01 | 4 | CMA1, CTSG, ACE, GZMH |
1269868 | Muscle contraction | 3.44E−02 | 4.03E−01 | 1.00E+00 | 1.00E+00 | 9 | KCNIP1, RYR3, SCN2B, ATP1A4, ATP1B2, MYL1, KCNK17, NPPA, TNNI1 |
1269340 | Hemostasis | 6.57E−02 | 5.21E−01 | 1.00E+00 | 1.00E+00 | 20 | GNG8, CEACAM3, F2RL2, SERPINE2, APOA1, GNA14, PDE5A, ATP1B2, IL2RB, CTSW, ISLR, ITGAL, LCK, TGFB2, LEFTY2, RASGRP1, CD2, P2RX6, CD48, HBB |
1269171 | Adaptive Immune System | 1.32E−01 | 6.87E−01 | 1.00E+00 | 1.00E+00 | 23 | NRG1, HLA-DQA1, ZAP70, SH2D1B, CARD11, SLAMF7, SIGLEC8, ITGAL, ITGB7, ASB18, IER3, MRC2, KLRB1, LCK, RASGRP1, CD1C, CD3D, CD3E, CD3G, CD247, FBXL16, CD40LG, SH2D1A |
Down regulated genes | |||||||
1457780 | Neutrophil degranulation | 4.82E−06 | 3.14E−03 | 2.22E−02 | 3.14E−03 | 28 | SERPINA3, HK3, ACP3, HMOX2, CHI3L1, S100A8, S100A9, FCER1G, MGST1, HP, FGR, ALOX5, ANPEP, FPR1, CR1, ARG1, SLC11A1, SIGLEC9, GPR84, HPSE, PTX3, CRISPLD2, CD177, SIGLEC14, RNASE2, TLR2, ELANE, MCEMP1 |
1269907 | SLC-mediated transmembrane transport | 6.91E−04 | 4.74E−02 | 3.35E−01 | 4.51E−01 | 16 | HK3, SLC7A11, SLC4A7, SLC1A1, SLC2A1, SLC5A1, SLC11A1, SLC22A16, SLCO2A1, SLCO4A1, GCKR, LCN15, SLC9A7, SLC25A18, SLC38A4, RHAG |
1269545 | Class A/1 (Rhodopsin-like receptors) | 8.72E−04 | 4.74E−02 | 3.35E−01 | 5.69E−01 | 17 | OPN4, SAA1, AGTR1, CCR1, CNR1, P2RY12, FPR1, SSTR2, SSTR5, KNG1, GPR4, GPR183, RGR, S1PR3, EDN1, EDN2, EDNRB |
1269340 | Hemostasis | 2.18E−03 | 7.11E−02 | 5.02E−01 | 1.00E+00 | 26 | SERPINA3, CD109, SLC7A11, F5, F8, F13A1, SERPINB8, FCER1G, FGR, MERTK, SERPINF2, SELE, P2RY12, APOB, KIF18B, ATP2A2, NHLRC2, KNG1, PDE11A, CD177, DOCK9, GRB7, GRB14, THBS1, SERPINE1, SERPINA5 |
1269903 | Transmembranetransport of small molecules | 4.89E−03 | 1.28E−01 | 9.01E−01 | 1.00E+00 | 26 | HK3, TRPC4, CFTR, HMOX2, SLC7A11, ABCB1, SLC4A7, AQP3, AQP4, SLC1A1, SLC2A1, SLC5A1, SLC11A1, SLC22A16, SLCO2A1, ATP2A2, GABRR2, SLCO4A1, GCKR, LCN15, SLC9A7, WNK3, SLC25A18, SLC38A4, RHAG, STEAP3 |
1269203 | Innate Immune System | 9.62E−03 | 1.96E−01 | 1.00E+00 | 1.00E+00 | 42 | SERPINA3, EREG, HK3, MARK3, ACP3, CLEC7A, HMOX2, CHI3L1, S100A8, S100A9, SAA1, FCER1G, MGST1, FCGR3A, HP, GRAP2, PLA2G2A, FGF5, FGF10, FGR, ALOX5, ANPEP, FPR1, APOB, CR1, FCN3, ARG1, SLC11A1, SIGLEC9, GPR84, HPSE, PTX3, WASF1, CRISPLD2, CD177, SIGLEC14, LBP, RNASE2, TLR2, ELANE, IRAK3, MCEMP1 |
1269310 | Cytokine Signaling in Immune system | 8.42E−02 | 4.76E−01 | 1.00E+00 | 1.00E+00 | 23 | EREG, MARK3, F13A1, SAA1, FGF5, CCR1, FGF10, ALOX5, IL17RB, FLT3, FPR1, SAMHD1, IL10, IL15RA, IL20RA, BCL6, IL18R1, IL1R2, SOCS3, LBP, IRAK3, IL1RL1, OSMR |